# Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

> **NCT02970305** · PHASE2 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 403 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Pimavanserin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02970305
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-04
- **Primary completion:** 2019-10-16
- **Final completion:** 2019-10-28
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970305, "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02970305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*